New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
10:59 EDTRHT, MTOR, ARWR, SWHC, PIR, VRTX, JBL, BBRY, SBGI, OHRPOptions with decreasing implied volatility
Options with decreasing implied volatility: OHRP VRTX ARWR SBGI PIR MTOR BBRY SWHC RHT JBL
News For OHRP;VRTX;ARWR;SBGI;PIR;MTOR;BBRY;SWHC;RHT;JBL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 20, 2014
16:17 EDTRHTRed Hat initiated with a Hold at Jefferies
Subscribe for More Information
12:19 EDTPIRWilliams-Sonoma hits 52-wk high after Q3 results beat estimates, raises outlook
Subscribe for More Information
November 19, 2014
15:53 EDTBBRYSome make case for Yahoo considering BlackBerry acquistion, Re/code says
Sources close to Yahoo (YHOO) said the company has been considering several "big acquisitions," largely aimed at helping its display business, and is eyeing tech-related companies including MediaMath, RadiumOne and Turn, reported Re/code's Kara Swisher. Swisher added that "one of the most far-out" ideas that has been "floated by bankers and other sundry pundits" is that Yahoo should buy BlackBerry (BBRY), and Swisher said that while that may seem unlikely, such a purchase would be "well within the amount" that Yahoo CEO Marissa Mayer has to spend. Reference Link
15:05 EDTBBRYBlackBerry CEO's forecasting skills under scrutiny, WSJ says
After Morgan Stanley suggested that BlackBerry may miss its revenue target for software sales, the forecasting skills of BlackBerry CEO John Chen may come under scrutiny, says the Wall Street Journal. According to the report, Chen, known as a turnaround expert, has said the smartphone maker will double its software sales to $500M in its next fiscal year. The Morgan Stanley analyst who wrote the report, James Faucette, said in the note, “We are skeptical that BlackBerry will be able to achieve that level of success, particularly with a new product platform, new pricing and with a still very damaged brand,” added the Wall Street Journal. Reference Link
13:42 EDTVRTXVertex peak CF sales have bullish read from Royalty Pharma bet, TheStreet says
Subscribe for More Information
12:18 EDTBBRYBlackBerry sinks after Morgan Stanley cuts to Underweight
Shares of BlackBerry (BBRY) are sinking after Morgan Stanley downgraded the stock to Underweight, saying that the market had become too optimistic about the outlook for the company's software and messaging platform. WHAT'S NEW: BlackBerry's valuation indicates that the market expects the company's software revenue and messaging revenue to increase by $250M and $100M, respectively, in fiscal 2016, Morgan Stanley analyst James Faucette wrote in a note to investors before the market opened today. These expectations are consistent with the targets set by the device maker's CEO, John Chen, Faucette stated. But the outlook "seems excessive," as they imply that BlackBerry will retain all of its enterprise subscribers, and convince them to pay the company three times more money than now, the analyst stated. BlackBerry will not "gain relevancy in the enterprise mobile management software market and will continue to lose enterprise subscribers," Faucette believes. He downgraded the stock to Underweight from Equal Weight and set a $7 price target on the shares. WHAT'S NOTABLE: In September, BlackBerry reported that it had issued 3.4M licenses for its BES10 mobile device management system during its September quarter representing a nearly threefold increase over the previous quarter. The company stated that BlackBerry Messenger had 91M users, up from 85M users the previous quarter. In a note to investors on November 14, JPMorgan raised its price target on the stock to $13 from $10. The company's product announcements on November 13 increased the chances that its software strategy will work, according to the firm. JPMorgan added, however, that BlackBerry still had a long road back to health, and kept a Neutral rating on the shares. PRICE ACTION: In late morning trading, BlackBerry slid 5% to $10.20.
10:42 EDTVRTXUBS hosts a conference call with Vertex Pharmaceuticals
Subscribe for More Information
10:00 EDTBBRYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Beacon Roofing (BECN) downgraded to Hold from Buy at KeyBanc... BlackBerry (BBRY) downgraded to Underweight from Equal Weight at Morgan Stanley... Consolidated Edison (ED) downgraded to Sell from Neutral at UBS... Denbury Resources (DNR) downgraded to Hold from Buy at Wunderlich... Synchronoss (SNCR) downgraded to Underperform from Neutral at RW Baird... Total System (TSS) downgraded to Sell from Neutral at Goldman... Movado (MOV) downgraded to Market Perform from Outperform at Barrington... Transocean Partners (RIGP) downgraded to Market Perform from Outperform at Wells Fargo... Seadrill Partners (SDLP) downgraded to Market Perform from Outperform at Wells Fargo... Petrobras (PBR) downgraded to Neutral from Buy at UBS.
09:16 EDTBBRYOn The Fly: Pre-market Movers
Subscribe for More Information
07:57 EDTBBRYBlackBerry downgraded at Morgan Stanley
Subscribe for More Information
07:52 EDTVRTXInforma Business Information to hold a conference
Subscribe for More Information
07:27 EDTVRTXRoyalty Pharma acquires royalties on Vertex Pharmaceuticals CF treatments
Subscribe for More Information
06:13 EDTBBRYBlackBerry downgraded to Underweight from Equal Weight at Morgan Stanley
November 18, 2014
07:36 EDTJBLUBS to hold a conference
Global Technology Conference to be held in Sausalito, California on November 18-20 with webcasted company presentations to begin on November 18 at 10:45 am; not all company presentations may be webcasted. Webcast Link
07:32 EDTARWRArrowhead files for regulatory permission to begin Phase I ARC-AAT trial
Arrowhead Research recently filed an application for approval to begin a Phase 1 clinical trial of its RNAi-based therapeutic candidate, ARC-AAT, for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Pending approval, Arrowhead intends to proceed with a double blind, placebo-controlled dose escalation, Phase 1 study to determine the safety, tolerability, pharmacokinetics and effect on circulating alpha-1 antitrypsin levels of ARC-AAT in healthy volunteers and patients with alpha-1 antitrypsin deficiency. The study is planned to start in Australia in healthy volunteers and will dose escalate until predetermined levels of alpha-1 antitrypsin reduction are reached. Once these levels of protein knockdown are achieved, the study will transition into a population of patients with ZZ genotype alpha-1 antitrypsin deficiency to further evaluate escalating doses of ARC-AAT. The study is designed to enroll up to 48 subjects, including healthy volunteers and alpha-1 antitrypsin deficiency patients. The application was submitted to an ethics committee in compliance with the Clinical Trial Notification process of the Australian Department of Health and Ageing, Therapeutic Goods Administration.
November 14, 2014
16:26 EDTBBRYNasdaq clear leader as major averages end week higher
Subscribe for More Information
10:00 EDTMTOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:20 EDTBBRYBlackBerry price target raised to $13 from $10 at JPMorgan
Subscribe for More Information
07:19 EDTBBRYBlackBerry new partnerships positive, but still early days, says RBC Capital
RBC Capital believes that BlackBerry has recruited good partners and distributors, but the firm thinks it's still unclear whether BES 12 can gain share from other Enterprise Mobility Management systems. RBC Capital keeps a $12 price target and Sector Perform rating on BlackBerry.
05:27 EDTMTORMeritor downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Meritor to Neutral citing limited upside potential following the outperformance of shares. Goldman upped its price target for the stock to $15 from $14.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use